Personal information

Websites & social links

Google Scholar Citations

Activities

Collapse all

Works (46)

Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study

AIDS and Behavior
2024-09-03 | Journal article
DOI: 10.1007/s10461-024-04479-9
Part of ISSN: 1090-7165
Part of ISSN: 1573-3254
Contributors: Princy Kumar; Amanda E. Clarke; Celia Jonsson-OldenbĆ¼ttel; Miguel GarcĆ­a Deltoro; Simona Di Giambenedetto; Carlos Brites; Laurent Hocqueloux; Po-Liang Lu; James Oyee; Alan Oglesby et al.
Source: Self-asserted source
Bryn Jones

TD-8ā€…Similar efficacy, safety and CD4 T cell increase up to week 96 observed in fostemsavir (FTR) based regimens from the BRIGHTE study and dolutegravir (DTG) based regimens from the VIKING-3 study in multidrug resistant (MDR) HIV-1 individuals

Themed Discussion
2024-06 | Conference abstract
DOI: 10.1136/sextrans-icar-2024.121
Contributors: A Castagna; N Gregori; I Marcon; F Du; B Li; M Wang; B Jones; M Prakash; A Clark
Source: Self-asserted source
Bryn Jones

Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis

Open Forum Infectious Diseases
2024-06-28 | Journal article
DOI: 10.1093/ofid/ofae365
Part of ISSN: 2328-8957
Contributors: Stefan Scholten; Pedro Cahn; JoaquĆ­n Portilla; Fiona Bisshop; Sally Hodder; Peter Ruane; Richard Kaplan; Brian R Wynne; Choy Y Man; Richard Grove et al.
Source: Self-asserted source
Bryn Jones

Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled <scp>TANGO</scp> and <scp>SALSA</scp> studies

HIV Medicine
2024-05-17 | Journal article
DOI: 10.1111/hiv.13643
Part of ISSN: 1464-2662
Part of ISSN: 1468-1293
Contributors: C. Katlama; F. Bisshop; J. Bogner; M. J. PĆ©rez ElĆ­as; S. Di Giambenedetto; E. Clarke; S. Hodder; N. Nwokolo; M. Aitā€Khaled; J. Oyee et al.
Source: Self-asserted source
Bryn Jones
grade
Preferred source (of 2)ā€Ž

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

The Lancet HIV
2024-03 | Journal article
DOI: 10.1016/s2352-3018(23)00292-8
Part of ISSN: 2352-3018
Contributors: Graeme Moyle; Lambert Assoumou; Nathalie de Castro; Frank A Post; Adrian Curran; Stefano Rusconi; Stephane De Wit; Christoph Stephan; FranƧois Raffi; Margaret Johnson et al.
Source: Self-asserted source
Bryn Jones

Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 agedā€‰ā‰„ā€‰50 years: week 48 pooled results from the TANGO and SALSA studies

AIDS Research and Therapy
2024-03-21 | Journal article
DOI: 10.1186/s12981-024-00604-9
Part of ISSN: 1742-6405
Contributors: Sharon Walmsley; Don E. Smith; Miguel GĆ³rgolas; Pedro E. Cahn; Thomas Lutz; Karine Lacombe; Princy N. Kumar; Brian Wynne; Richard Grove; Gilda Bontempo et al.
Source: Self-asserted source
Bryn Jones

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies

Viruses
2024-03-06 | Journal article | Author
DOI: 10.3390/v16030405
Part of ISSN: 1999-4915
Contributors: Mark Underwood; Rimgaile Urbaityte; Ruolan Wang; Joe Horton; James Oyee; Brian Wynne; Dainielle Fox; Bryn Jones; Choy Man; Jƶrg Sievers
Source: Self-asserted source
Bryn Jones
grade
Preferred source (of 3)ā€Ž

EfficacitƩ durable du switch d'un rƩgime 3-4DR Ơ base de TAF vers un rƩgime 2DR DTG/3TC dans l'Ʃtude TANGO jusqu'Ơ S196

MĆ©decine et Maladies Infectieuses Formation
2023 | Journal article
Contributors: Bonnet, F; Olalla, J; Routy, J-P; Wang, R; Saggu, P; Wynne, B; Jones, B; Ait-Khaled, M; Robineau, O; others
Source: Self-asserted source
Bryn Jones

EfficacitĆ© Ć©levĆ©e du DTG/3TC chez les adultes naĢˆÄ±fs de traitement avec une CV initiale Ć©levĆ©e: analyses de sous-groupes Ć  S48 des essais GEMINI-1/-2 et STAT

MĆ©decine et Maladies Infectieuses Formation
2023 | Journal article
Contributors: Rolle, C-P; Arribas, J; Ortiz, R; Matthews, J; Man, C; Grove, R; Wynne, B; Kisare, M; Jones, B; Lacombe, K
Source: Self-asserted source
Bryn Jones

Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: 3-Year Results of the Randomized TANGO Study

Open Forum Infectious Diseases
2023 | Conference paper
Contributors: Wang, Ruolan; Underwood, Mark; Llibre, Josep M; Morell, Enrique Bernal; Brinson, Cynthia; Moreno, JosƩ Sanz; Scholten, Stefan; Moore, Richard; Saggu, Parminder; Oyee, James et al.
Source: Self-asserted source
Bryn Jones

Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis

Open Forum Infectious Diseases
2023 | Conference paper
Contributors: Kabra, Madhusudan; Barber, Tristan J; Allavena, Clotilde; Marcelin, Anne-GeneviĆØve; Di Giambenedetto, Simona; Pasquau, Juan; Gianotti, Nicola; Llibre, Josep M; Rial-Crestelo, David; De Miguel-Buckley, Rosa et al.
Source: Self-asserted source
Bryn Jones

Virologic Response to Dolutegravir+ Lamivudine in People With Suppressed HIV-1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis

Open Forum Infectious Diseases
2023 | Conference paper
Contributors: Kabra, Madhusudan; Barber, Tristan J; Allavena, Clotilde; Marcelin, Anne-GeneviĆØve; Di Giambenedetto, Simona; Pasquau, Juan; Gianotti, Nicola; Llibre, Josep M; Rial-Crestelo, David; De Miguel-Buckley, Rosa et al.
Source: Self-asserted source
Bryn Jones

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings

Viruses
2023-12-14 | Journal article
DOI: 10.3390/v15122426
Contributors: Cassidy Henegar; Emilio Letang; Ruolan Wang; Charles Hicks; Dainielle Fox; Bryn Jones; Annemiek de Ruiter; Vani Vannappagari
Source: check_circle
Crossref
grade
Preferred source (of 2)ā€Ž

Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine (DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis.

Infection & Chemotherapy
2022 | Journal article
Contributors: Llibre, Josep M; Scholten, Stefan; Osiyemi, Olayemi; Grove, Richard; Oyee, James; Wang, Ruolan; Wynne, Brian; Donovan, Cynthia; Jones, Bryn; Okoli, Chinyere et al.
Source: Self-asserted source
Bryn Jones

Durable efficacy of switching from a three-/four-drug tenofovir alafenamide (TAF)-based regimen to the two-drug regimen dolutegravir/lamivudine (DTG/3TC) in the TANGO study through week 196

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2022 | Conference paper
Contributors: De Wit, S; Bonnet, F; Osiyemi, O; Bisshop, F; Olalla, J; Routy, J; Wyen, C; Moodley, R; Pappa, K; Wang, R et al.
Source: Self-asserted source
Bryn Jones

Effectiveness of dolutegravir plus lamivudine in real-world studies in people with HIV-1 with M184V/I mutations: a systematic review and meta-analysis

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2022 | Conference paper
Contributors: Kabra, M; Barber, T; Allavena, C; Marcelin, A; di Giambenedetto, S; Pasquau, J; Gianotti, N; Turner, M; Harrison, C; Wynne, T et al.
Source: Self-asserted source
Bryn Jones

Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in Black and Asian participants from TANGO and SALSA: pooled 48-week data analyzed by race

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2022 | Conference paper
Contributors: Kumar, P; Hagins, D; Andrade-Villanueva, J; Lu, P; Adachi, E; Rubio, R; Lutz, T; Ait-Khaled, M; Grove, R; Wynne, B et al.
Source: Self-asserted source
Bryn Jones

Efficacy and safety of switching to dolutegravir plus rilpivirine in virologically suppressed older PLWHIV: pooled week 148 results from SWORD-1 and SWORD-2

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2022 | Conference paper
Contributors: Prakash, M; Grove, R; Wynne, B; van Wyk, J; Jones, B; Clark, A
Source: Self-asserted source
Bryn Jones

Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Agedā‰„ 50 Years: Pooled Results From the TANGO and SALSA Studies.

Infection & Chemotherapy
2022 | Journal article
Contributors: Walmsley, Sharon; Smith, Don E; GĆ³rgolas, Miguel; Cahn, Pedro E; Lutz, Thomas; Lacombe, Karine; Kumar, Princy N; Wynne, Brian; Grove, Richard; Bontempo, Gilda et al.
Source: Self-asserted source
Bryn Jones

Efficacy and Safety of Switching to Dolutegravir/Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis.

Infection & Chemotherapy
2022 | Journal article
Contributors: Scholten, Stefan; Cahn, Pedro; Ruane, Peter; Kaplan, Richard; Portilla, JoaquĢÄ±n; Hodder, Sally; Bisshop, Fiona; Wynne, Brian R; Grove, Richard; Bontempo, Gilda et al.
Source: Self-asserted source
Bryn Jones

High efficacy of dolutegravir/lamivudine (DTG/3TC) in treatment-naive adults with HIV-1 and high baseline viral load (VL): 48-week subgroup analyses of the GEMINI-1/-2 and STAT trials

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2022 | Conference paper
Contributors: Rolle, C; Arribas, J; Ortiz, R; Matthews, J; Man, C; Grove, R; Donovan, C; Wynne, B; Kisare, M; Jones, B
Source: Self-asserted source
Bryn Jones

Lipid changes in real-world studies with the two-drug regimen dolutegravir and lamivudine (DTG+ 3TC) in people with HIV-1: a systematic literature review

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2022 | Conference paper
Contributors: Letang, E; Lo, J; Milinkovic, A; Maggiolo, F; di Giambenedetto, S; Mussini, C; Yoruk, I Ungan; Henegar, C; Priest, J; Young, B et al.
Source: Self-asserted source
Bryn Jones

Real-world data from the prospective, multicentre study on the use of dolutegravir-based regimens (DBRs) in ART-naive and experienced people living with HIV: 12-month results from the Russian TESLA study

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2022 | Conference paper
Contributors: Kuznetsov, S; Minaeva, S; Sizova, N; Nagimova, F; Orlova-Morozova, E; Radzikhovskaya, M; Shevchenko, V; Maldonado, A; Jones, B
Source: Self-asserted source
Bryn Jones

Real-world experience with the two-drug regimen dolutegravir and lamivudine in women with HIV: a systematic literature review

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2022 | Conference paper
Contributors: di Giambenedetto, S; Walmsley, S; Grinsztejn, B; Perez-Elias, M; Nwokolo, N; Kabra, M; Jones, B; Letang, E; Kisare, M
Source: Self-asserted source
Bryn Jones

Risk Factors for Suboptimal Adherence Identified by Patient-Reported Outcomes Assessments in Routine HIV Care at 2 North American Clinics

Patient preference and adherence
2022 | Journal article
Contributors: Short, Duncan; Wang, Xueqi; Suri, Shivali; Hsu, Thomas K; Jones, Bryn; Fredericksen, Rob J; Crane, Heidi M; Musten, Alexandra; Bacon, Jean; Wang, Yongwei et al.
Source: Self-asserted source
Bryn Jones

Systematic literature review of real-world experience with the two-drug regimen dolutegravir and lamivudine in people with HIV who would not have met inclusion criteria for the phase III clinical program

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2022 | Conference paper
Contributors: Slim, J; Ward, D; Schneider, S; Kabra, M; Verdier, G; Jones, B; Letang, E
Source: Self-asserted source
Bryn Jones

1267. Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ā‰„65 Years: Pooled Results from the TANGO and SALSA Studies

Open Forum Infectious Diseases
2022-12-15 | Journal article
DOI: 10.1093/ofid/ofac492.1098
Part of ISSN: 2328-8957
Contributors: Manyu Prakash; Richard Grove; Brian R Wynne; Choy Man; Jean A van Wyk; Clifford B Jones; Chinyere Okoli; Emilio Letang; Mounir Ait-Khaled; Andrew Clark
Source: Self-asserted source
Bryn Jones

1285. Systematic Literature Review of Real-world Experience with the 2-Drug Regimen Dolutegravir and Lamivudine in People with HIV Who Would Not Have Met Inclusion Criteria for the Phase 3 Clinical Program

Open Forum Infectious Diseases
2022-12-15 | Journal article
DOI: 10.1093/ofid/ofac492.1116
Part of ISSN: 2328-8957
Contributors: Jihad Slim; Douglas Ward; Stefan Schneider; Madhusudan Kabra; Gustavo Verdier; Clifford B Jones; Emilio Letang
Source: Self-asserted source
Bryn Jones

Brief report: improvement in metabolic health parameters at week 48 after switching from a tenofovir alafenamide--based 3-or 4-drug regimen to the 2-drug regimen of dolutegravir/lamivudine: the TANGO study

Journal of Acquired Immune Deficiency Syndromes (1999)
2021 | Journal article
Contributors: van Wyk, Jean; Ait-Khaled, Mounir; Santos, Jesus; Scholten, Stefan; Wohlfeiler, Michael; Ajana, FaĢˆÄ±za; Jones, Bryn; Nascimento, Maria-Claudia; Tenorio, Allan R; Smith, Don E et al.
Source: Self-asserted source
Bryn Jones

Understanding the perceived therapeutic need and value associated with novel long-acting antiretroviral regimens among people living with HIV in 12 European countries

EACS
2021 | Journal article
Contributors: Dakhia, Samia; Jones, Bryn; Brough, Garry; Garcia, Diego; Appiah, Ama; de los Rios, Patricia
Source: Self-asserted source
Bryn Jones

Improved metabolic parameters after switching from TAF-based 3-or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): the TANGO study

23rd international AIDS conference
2020 | Conference paper
Contributors: van Wyk, Jean; Ait-Khaled, Mounir; Santos, Jesus; Scholten, Stefan; Wohlfeiler, Michael; Ajana, Faiza; Jones, Bryn; Nascimento, Maria Claudia; Tenorio, Allan; Smith, D et al.
Source: Self-asserted source
Bryn Jones

SWORD 1&2: maintenance or improvement in renal function in PLWH through 148 weeks after switch to the dolutegravir plus rilpivirine 2-drug regimen

HIV MEDICINE
2019 | Conference paper
Contributors: Llibre, JM; Voronin, E; Rubio, R; Girard, PM; Bredeek, F; van Wyk, J; Kahl, L; Jones, B; Curtis, L; Wynne, B et al.
Source: Self-asserted source
Bryn Jones

Localized cyclical variations in immunoproteins in the female genital tract and the implications on the design and assessment of mucosal infection and therapies

American Journal of Reproductive Immunology
2018 | Journal article
Contributors: Makinde, Julia; Jones, Clifford; Bartolf, Angela; Sibeko, Sengeziwe; Baden, Susan; Cosgrove, Catherine; Shattock, Robin J
Source: Self-asserted source
Bryn Jones

MIP-3 alpha does not appear to play an important role in amplifying human infection with HIV-1 in the female genital tract

HIV MEDICINE
2018 | Conference paper
Contributors: Sibeko, S; Herrera, C; Andrews, S; Ekeruche-Makinde, J; Olejniczak, N; Aldonn, Y; Evans, A; James, K; Moore, R; Dhar, S et al.
Source: Self-asserted source
Bryn Jones

Safety and efficacy of dolutegravir in treatment naive patients, 50 years and over: subgroup analysis of 48-week results from SPRING-2, SINGLE, FLAMINGO and ARIA

HIV MEDICINE
2017 | Conference paper
Contributors: Okoli, C; Murungi, A; Paice, A; Jones, B; Benn, P; Aboud, M; Barthel, FMS; Koteff, J; Wynne, B
Source: Self-asserted source
Bryn Jones

How the use of social media and online platforms can enhance recruitment to HIV clinical trials

2015 | Journal article
Contributors: Rellis, L; Haidari, G; Ridgers, H; Jones, CB; Miller, A; Shattock, R; McCormack, S; Brodnicki, E; Banbury, S
Source: Self-asserted source
Bryn Jones

Plasmid DNA vaccine co-immunisation modulates cellular and humoral immune responses induced by intranasal inoculation in mice

Plos one
2015 | Journal article
Contributors: King, Deborah FL; McKay, Paul F; Mann, Jamie FS; Jones, C Bryn; Shattock, Robin J
Source: Self-asserted source
Bryn Jones

Can we measure HIV viral load in mucosal secretions in men?

HIV MEDICINE
2014 | Conference paper
Contributors: Jones, C; Kaye, S; Shattock, R; Fidler, S
Source: Self-asserted source
Bryn Jones

What are the best methods to recruit healthy volunteers into HIV vaccine trials?

HIV MEDICINE
2014 | Conference paper
Contributors: Jones, C; Quinn, K; Miller, A; O'Farrell, S; Legg, K; Shattock, R; McCormack, S
Source: Self-asserted source
Bryn Jones

Evaluation of an HIV risk score within an outpatient sexual health clinic

HIV medicine
2013 | Journal article
Contributors: Jones, C; Kuldanek, K; Vickerman, P; Smith, A; Fox, J; Platt, L; Fidler, S
Source: Self-asserted source
Bryn Jones

Strategies to guide HIV prevention approaches: Correlation of sexually transmitted infections and sexual behaviour with risk of HIV infection

HIV medicine
2013 | Journal article
Contributors: Jones, C; Kuldanek, K; Phekoo, K; Greene, L; Smith, A; Platt, L; Fidler, S
Source: Self-asserted source
Bryn Jones

Analysis of post-exposure prophylaxis history among high-risk GUM attendees

HIV MEDICINE
2012 | Conference paper
Contributors: Jones, C; Kuldanek, K; Phekoo, K; Platt, L; Smith, A; Fidler, S
Source: Self-asserted source
Bryn Jones

Clinical evaluation of the Determine HIV-1/2 Ag/Ab combo test

The Journal of infectious diseases
2012 | Journal article
Contributors: Jones, Clifford B; Kuldanek, Kristin; Muir, David; Phekoo, Karen; Black, Adam; Sacks, Rachel; Smith, Alan; Fidler, Sarah
Source: Self-asserted source
Bryn Jones

Missed opportunities for identifying primary HIV within genitourinary medical/HIV services

International journal of STD & AIDS
2012 | Journal article
Contributors: Sharrocks, K; Jones, CB; Naftalin, C; Darling, D; Fisher, M; Fidler, S; Fox, J
Source: Self-asserted source
Bryn Jones

Treatment as prevention: the views of high risk patients attending an outpatient GUM clinic

HIV MEDICINE
2012 | Conference paper
Contributors: Jones, C; Kuldanek, K; Phekoo, K; Platt, L; Smith, A; Fidler, S
Source: Self-asserted source
Bryn Jones

Switch to Dolutegravir/Rilpivirine in Virologically Suppressed, Antiretroviral Treatment-Experienced HIV-1 Infected Individuals with K103N Mutation: 48-Week Results of a Randomised, Pilot Clinical Trial

WISARD (sWItch Study mutAtion Rilpivirine Dolutegravir) Study Group
Journal article
Contributors: Moyle, Graeme; Assoumou, Lambert; De Castro, Nathalie; Post, Frank A; Curran, AdriĆ ; Russconi, Stefano; De Wit, Stephane; Stephan, Christoph; Raffi, Francois; Johnson, Margaret et al.
Source: Self-asserted source
Bryn Jones
How many people are using ORCID?